Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 12:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: iohexol GFR Clear all
Recruiting Phase 1 Interventional

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

NCT05065372
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions
Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo
Drug
Lead sponsor
Kalie Tommerdahl
Other
Eligibility
12 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 11, 2026, 12:17 PM EDT
Completed No phase listed Observational

PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)

NCT04407481
View directory record Official record
Conditions
Polycystic Kidney Disease, Adult, Polycystic Kidney, Autosomal Dominant
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams per milliliter (MG/ML), PET/CT Scan
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Sep 11, 2026, 12:17 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)

NCT05008276
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Adolescent Obesity, Pre Diabetes, Kidney Hypoxia, Puberty
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Dextran 40
Drug
Lead sponsor
Petter Bjornstad
Other
Eligibility
8 Years to 14 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 11, 2026, 12:17 PM EDT
Completed No phase listed Observational

Live Kidney Donor Study -Renal Function Study

NCT01158742
View directory record Official record
Conditions
Kidney Donation, Kidney Failure, Kidney Transplantation
Interventions
Glomerular Filtration Rate with Iothalamate, Glomerular Filtration Rate with Iohexol
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 11, 2026, 12:17 PM EDT
Completed No phase listed Observational

Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance

NCT01545531
View directory record Official record
Conditions
Renal Disease, Renal Insufficiency
Interventions
Iohexol
Drug
Lead sponsor
University of Washington
Other
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 11, 2026, 12:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects

NCT07809919
View directory record Official record
Conditions
Visceral Leishmaniasis, Chagas Disease
Interventions
LXE408, Placebo, Iohexol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 11, 2026, 12:17 PM EDT
Completed No phase listed Observational

Comparison of Markers of Kidney Function

NCT01403766
View directory record Official record
Conditions
Chronic Kidney Disease, Renal Insufficiency
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 11, 2026, 12:17 PM EDT
Completed No phase listed Observational

Effect of Hormone Therapy on Renal Function

NCT04482920
View directory record Official record
Conditions
Transgenderism, Kidney Diseases, Kidney Injury
Interventions
p-aminohippurate clearance study, Iohexol infusion
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
17 Years to 30 Years
Enrollment
22 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 11, 2026, 12:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.

NCT01978314
View directory record Official record
Conditions
Chronic Kidney Disease, Acute Kidney Injury
Interventions
75 mg / 6 mL VFI™
Device
Lead sponsor
FAST BioMedical
Industry
Eligibility
19 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 11, 2026, 12:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of MP-3180 in Healthy Volunteers

NCT02098174
View directory record Official record
Conditions
Glomerular Filtration Rate, Acute Kidney Injury
Interventions
MP-3180, Iohexol comparator
Drug · Other
Lead sponsor
MediBeacon
Industry
Eligibility
22 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 11, 2026, 12:17 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Measurement of Renal Function With Iohexol in Subjects Ingesting Carnitine

NCT01392313
View directory record Official record
Conditions
Carnitine Ingestion
Interventions
Carnitine, Placebo
Dietary Supplement
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Sep 11, 2026, 12:17 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study

NCT03584217
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity, Nephropathy, Adolescent Obesity
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Renal Biopsy
Drug · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 11, 2026, 12:17 PM EDT
Active, not recruiting No phase listed Observational

Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)

NCT05319990
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Kidney Disease, Diabetes Complications, Diabetic Nephropathies, Autoimmune Diabetes
Interventions
Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF), Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 11, 2026, 12:17 PM EDT
Not yet recruiting Phase 4 Interventional

Fluorescent Probe for Assessment of Renal Elimination

NCT07643467
View directory record Official record
Conditions
Augmented Renal Clearance, Critical Illness
Interventions
Relmapirazin, Iohexol, Medibeacon tGFR monitor, Urine creatinine clearance collection
Drug · Device · Diagnostic Test
Lead sponsor
Aaron Cook
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 11, 2026, 12:17 PM EDT
Completed No phase listed Observational Results available

Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study

NCT05530356
View directory record Official record
Conditions
Type 2 Diabetes, Diabetes Type 2, Diabetic Nephropathies, Nephropathy, Obesity, Adolescent Obesity, Diabetic Kidney Disease
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Dextran 40, Renal Biopsy, Positron Emission Tomography
Drug · Procedure · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 26 Years
Enrollment
57 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 11, 2026, 12:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

NCT02772276
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
MB-102-- single dose of 4 µmol/kg, MB-102-- single dose of 130 mg, MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart, MB-102-- two doses of 130 mg 24 hours apart, Iohexol, QuantumLeap, Radiance, Brilliance (1 or 2 sensors), Brilliance (2-part sensor)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
3
States / cities
Edgewater, Florida • Orlando, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 11, 2026, 12:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers

NCT02098187
View directory record Official record
Conditions
Glomerular Filtration Rate, Acute Kidney Injury
Interventions
Below target dose MP-3180, At target dose MP-3180, 2 times above target dose MP-3180, 4 times above target dose MP-3180, ORFM prototype, Iohexol comparator
Drug · Device · Other
Lead sponsor
MediBeacon
Industry
Eligibility
22 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Sep 11, 2026, 12:17 PM EDT
Completed Not applicable Interventional Results available

Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS

NCT02276066
View directory record Official record
Conditions
Sepsis
Interventions
GFR by Iohexol, Urine Collection, Blood samples
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 11, 2026, 12:17 PM EDT
Terminated No phase listed Observational

Evaluation of Renal Function in Subjects Who Had Undergone Cardiac Surgery

NCT04654221
View directory record Official record
Conditions
Cardiac Surgery
Interventions
mGFR by iohexol clearance
Diagnostic Test
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Mobile, Alabama • Covina, California • Northridge, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 11, 2026, 12:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function

NCT03618420
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Nephropathy, Diabetic Nephropathies, Juvenile Diabetes, Diabetes Mellitus Complication, Autoimmune Diabetes, Type 1 Diabetes Mellitus
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 11, 2026, 12:17 PM EDT
Terminated Phase 1 Interventional

A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease

NCT01839526
View directory record Official record
Conditions
Fabry Disease
Interventions
Iohexol
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
5 Years to 25 Years · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
La Jolla, California • Decatur, Georgia • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Sep 11, 2026, 12:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects

NCT02229214
View directory record Official record
Conditions
Obesity
Interventions
Qsymia, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 11, 2026, 12:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance

NCT04074668
View directory record Official record
Conditions
Diabetic Kidney Disease, Type 1 Diabetes, Diabetes, Diabetes Mellitus, Diabetes Complications, Diabetic Nephropathies, Type1diabetes, Diabetes, Autoimmune, Autoimmune Diabetes, Juvenile Diabetes, Type 1 Diabetes Mellitus
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams/milliliter (mg/ml), PET/CT Scan, Renal Biopsy
Drug · Radiation · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 11, 2026, 12:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia

NCT04380610
View directory record Official record
Conditions
Sickle Cell Disease, Renal Disease, Glomerular Disease
Interventions
iohexol GFR
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
5 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 11, 2026, 12:17 PM EDT